... (TACE) had poor prognoses. Recent advancements in hepatic arterial infusion chemotherapy (HAIC) and immune checkpoint inhibitors (ICIs) have demonstrated higher tumor response rates, which improved overall survival (OS). HAIC achieves an OS rate of approximately 14.5–15.3 months with a 39.1–42.5% tumor...

...Ahmed A. Refae; Rafat I. Abu Shakra; Ezzeldin M. Ibrahim Introduction: Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations face poor outcomes after progression on tyrosine kinase inhibitors (TKIs). The efficacy of immune checkpoint inhibitors...

... (NSCLC) patients receiving combined immunochemotherapy are exposed to short-course corticosteroids following immune checkpoint inhibitor (ICI) infusion to prevent chemotherapy-related adverse events. However, whether this early short-course corticosteroid use prevents immune-related adverse events (irAEs...

...Cho-Han Chiang; Yuan-Jen Chen; Xin Ya See; Yu-Cheng Chang; Shih-Syuan Wang; Chun-Yu Peng; Chuan-Sheng Horng; Yuan Ping Hsia; Cho-Hung Chiang; Cheng-Ming Peng; Cho-Hsien Chiang Background: Statins are associated with improved survival outcomes in patients receiving immune checkpoint inhibitors (ICIs...

... patients due to a generally weakened immune system. Immune checkpoint inhibitors (ICI) are expected to enhance immune response. This has already been described to be the case in influenza vaccines, and first data about COVID-19 vaccines show a trend in this direction. Aim: We aimed to investigate...

...Oded Jacobi; Yosef Landman; Daniel Reinhorn; Oded Icht; Michal Sternschuss; Ofer Rotem; Inbar Finkel; Aaron M. Allen; Elizabeth Dudnik; Daniel A. Goldstein; Alona Zer Introduction: Immune checkpoint inhibitors (ICI) are the new standard therapy in patients with metastatic NSCLC (mNSCLC). Metformin...

... counter the effects of immune checkpoint inhibitors. From this point of view, monotherapy of anti-PD-1/PD-L1 antibody might not be enough to exert a sufficient antitumor effect; additional blockade of immunosuppressive molecules in tumor microenvironment could enhance the antitumor effect of anti-PD-1/PD...

...Masatoshi Kudo Clinical trials of antibodies targeting the immune checkpoint inhibitors programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for the treatment of advanced hepatocellular carcinoma (HCC) are ongoing. Expansion...